Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Scientists from The Christie NHS Foundation Trust have begun human trials on the use of aspirin and avelumab in treating patients diagnosed with triple-negative breast cancer.
XVR011 is being observed in a randomized, double-blind, single-center, and placebo-controlled study to evaluate its pharmacokinetic activity and safety profile.
mRNA has built its reputation as a type of vaccine to fight COVID-19, but its capabilities extend beyond vaccines into therapeutics and even diagnostics.
The prototype offers PCR-like precision without a power-source, and is stable at room temperature for many months.
The latest biopharma insider trading scandal stems from Pfizer’s acquisition of Medivation in 2016.
Increase in application of AR in rehabilitation, diagnostic imaging, surgical simulation, and patient care management along with surge in number of AR-based startups propel the growth of the global AR in healthcare market.
Two months after Athira placed its CEO Leen Kawas, on temporary leave, the company has appointed new execs to its team. It is also rigorously advancing its Alzheimer’s program.
CureVac has revealed in its latest financial report that its lung cancer program with German biotechnology company Boehringer Ingelheim has been terminated.
The goal was to find and finance promising endeavors, including clinical trials that need a financial push, companies looking to expand globally, and firms that have experienced drops recently.
Moderna is expected to launch a human clinical trial as early as this week for an mRNA-based vaccine against HIV and indicated that it is looking for 56 people ages 18 to 50 who are HIV-negative.
The FDA recommended additional clinical and statistical data analyses of Vicineum, as well as issues related to the company’s Chemistry, Manufacturing, and Controls.
As COVID-19 surges to earlier pandemic levels in the U.S., federal health officials are expected to authorize a third booster shot eight months after receiving the second of the Moderna and Pfizer-BioNTech vaccines, and probably the Johnson & Johnson vaccine as well.